25 May 2020 - Roche secures TGA approval for another cancer medicine.

Rozlytrek was approved for the "treatment of adult patients with advanced non-small cell lung cancer whose tumours are ROS1-positive" on 15 May 2020.

Rozlytrek (entrectinib) is to be included in the TGA's Black Triangle Scheme.

Read TGA News